Alterity Therapeutics (PRNAD) Operating Leases (2019 - 2025)

Alterity Therapeutics (PRNAD) has reported Operating Leases for 7 consecutive years, with $56707.2 the latest figure, recorded in Q2 2025.

• In Q2 2025, Operating Leases rose 65.75% year-over-year to $56707.2; the TTM figure through Jun 2025 stood at $56707.2 (up 65.75% YoY), while the FY2025 annual figure was $56707.2, up 65.75% from the prior year.
• Operating Leases came in at $56707.2 for Q2 2025 at Alterity Therapeutics, up from $34212.6 in the prior quarter.
• The five-year high for Operating Leases was $68979.5 in Q2 2023, with the low at $29187.4 in Q2 2021.
• Average Operating Leases over 5 years is $46392.1, with a median of $42873.7 recorded in 2022.
• Across the five-year window, Operating Leases tumbled 50.4% in 2024 and soared 65.75% in 2025, its largest moves.
• Year by year, Operating Leases stood at $29187.4 in 2021, then jumped by 46.89% to $42873.7 in 2022, then surged by 60.89% to $68979.5 in 2023, then sank by 50.4% to $34212.6 in 2024, then jumped by 65.75% to $56707.2 in 2025.
• According to Business Quant data, Operating Leases over the past three periods registered $56707.2, $34212.6, and $68979.5 for Q2 2025, Q2 2024, and Q2 2023 respectively.